TY - JOUR
AU - Karnon, Jonathan
AB - Aromatase inhibitors (AIs) have been evaluated clinically in a wide range of breast cancer treatment settings. Although these agents appear to have clinical superiority, they are more expensive than the therapies (primarily tamoxifen) they have been compared with, thus economic evaluation is required to consider their incremental value to the payer. This paper reviews published economic evaluations of AIs as first-line therapy for advanced cancer, and as adjuvant therapy for early breast cancer.
TI - Aromatase Inhibitors in Breast Cancer
JF - PharmacoEconomics
DO - 10.2165/00019053-200624030-00002
DA - 2012-10-11
UR - https://www.deepdyve.com/lp/springer-journals/aromatase-inhibitors-in-breast-cancer-aGgz0irCBN
SP - 215
EP - 232
VL - 24
IS - 3
DP - DeepDyve
ER -